^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    volrustomig (MEDI5752)

    i
    Other names: MEDI5752, MEDI-5752, MEDI 5752
    Company:
    AstraZeneca
    Drug class:
    PD1 inhibitor, CTLA4 inhibitor
    Related drugs:
    20d
    eVOLVE-RCC02: A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC (clinicaltrials.gov)
    P3, N=1116, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • volrustomig (MEDI5752) • casdatifan (AB521)
    20d
    eVOLVE-Meso: MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma (clinicaltrials.gov)
    P3, N=825, Recruiting, AstraZeneca | Trial completion date: Mar 2028 --> Nov 2028 | Trial primary completion date: Mar 2027 --> Nov 2027
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • carboplatin • pemetrexed • volrustomig (MEDI5752)
    21d
    GEMINI-Hepatobiliary: Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer (clinicaltrials.gov)
    P2, N=294, Recruiting, AstraZeneca | Trial completion date: Dec 2026 --> Oct 2027 | Trial primary completion date: Dec 2025 --> Oct 2026
    Trial completion date • Trial primary completion date
    |
    Avastin (bevacizumab) • cisplatin • gemcitabine • Lenvima (lenvatinib) • rilvegostomig (AZD2936) • volrustomig (MEDI5752)
    1m
    eVOLVE-02: Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
    P2, N=110, Recruiting, AstraZeneca | N=257 --> 110
    Enrollment change
    |
    cisplatin • carboplatin • paclitaxel • volrustomig (MEDI5752)
    2ms
    Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03) (clinicaltrials.gov)
    P2, N=413, Recruiting, AstraZeneca | Trial completion date: Jul 2026 --> Jun 2027 | Trial primary completion date: Jul 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Keytruda (pembrolizumab) • cisplatin • Imfinzi (durvalumab) • 5-fluorouracil • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • oxaliplatin • rilvegostomig (AZD2936) • volrustomig (MEDI5752)
    2ms
    eVOLVE-02: Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors (clinicaltrials.gov)
    P2, N=257, Recruiting, AstraZeneca | N=110 --> 257 | Trial completion date: Oct 2027 --> Nov 2028 | Trial primary completion date: Oct 2027 --> Nov 2028
    Enrollment change • Trial completion date • Trial primary completion date
    |
    cisplatin • carboplatin • paclitaxel • volrustomig (MEDI5752)
    2ms
    CANTOR: A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer (clinicaltrials.gov)
    P2, N=120, Recruiting, AstraZeneca | Trial completion date: Jan 2028 --> Jun 2028
    Trial completion date
    |
    Avastin (bevacizumab) • 5-fluorouracil • irinotecan • leucovorin calcium • volrustomig (MEDI5752)
    3ms
    TROPION-Lung04: Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P1, N=165, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting | N=371 --> 165 | Trial completion date: Jan 2026 --> Apr 2026 | Trial primary completion date: Jan 2026 --> Apr 2026
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx • VENTANA PD-L1 (SP263) Assay • PD-L1 IHC 28-8 pharmDx
    |
    carboplatin • Imfinzi (durvalumab) • Datroway (datopotamab deruxtecan-dlnk) • rilvegostomig (AZD2936) • volrustomig (MEDI5752) • sabestomig (AZD7789)
    3ms
    eVOLVE-RCC02: A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC (clinicaltrials.gov)
    P3, N=1116, Recruiting, AstraZeneca | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • volrustomig (MEDI5752) • casdatifan (AB521)
    4ms
    DESTINY-Lung03: Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC (clinicaltrials.gov)
    P1, N=244, Recruiting, AstraZeneca | Trial completion date: Dec 2025 --> Jun 2027 | Trial primary completion date: Dec 2025 --> Jun 2027
    Trial completion date • Trial primary completion date • IO biomarker
    |
    HER-2 overexpression
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • pemetrexed • rilvegostomig (AZD2936) • volrustomig (MEDI5752)
    4ms
    eVOLVE-01: Volrustomig Priming Regimens Exploratory Phase II Platform Study (clinicaltrials.gov)
    P2, N=180, Recruiting, AstraZeneca | N=120 --> 180
    Enrollment change
    |
    carboplatin • paclitaxel • Cyramza (ramucirumab) • pemetrexed • volrustomig (MEDI5752)
    4ms
    MEDI5752 in Japanese Patients With Advanced Solid Tumors. (clinicaltrials.gov)
    P1, N=6, Completed, AstraZeneca | Active, not recruiting --> Completed
    Trial completion
    |
    volrustomig (MEDI5752)